Key takeaways
View moreAbbVie appears moderately undervalued based on its strong growth prospects in key products like Skyrizi and Rinvoq, improving free cash flow margin, and below-industry average EV/EBITDA ratio. The current stock price seems to be overly discounting risks such as patent expirations and high debt levels, while not fully reflecting the potential of the company's robust pipeline and strategic initiatives.
- AbbVie's revenue is growing, but its net profit margin is declining, decreasing from 11.04% in Q1 2024 to -0.21% in Q4 2024, due to increasing SG&A and unusual expenses.
- The company's liquidity position is weak, with a current ratio consistently below 1, indicating potential difficulties in meeting short-term obligations.
- AbbVie carries a high debt load, reflected in a debt-to-equity ratio of 2040.33 in Q4 2024, indicating significant financial leverage.
- Skyrizi and Rinvoq are key growth drivers, expected to generate nearly $24 billion in 2025, with combined sales exceeding $31 billion in 2027, as highlighted in the earnings call.
- The Medicare Part D redesign is a significant headwind, impacting revenue by approximately 4%, according to management guidance.
- AbbVie has underperformed the Health Care Select Sector SPDR Fund (XLV) year-to-date, with returns of -1.79% compared to XLV's -1.16%, indicating recent market challenges.
- The company's free cash flow margin has increased from 0.31 in Q1 to 0.45 in Q4, indicating improved cash generation relative to revenue.
- Strategic acquisitions, such as ImmunoGen and Cerevel Therapeutics, are aimed at expanding AbbVie's oncology and neuroscience pipelines, as detailed in SEC filings.
- Management expects total net revenues of approximately $59 billion in 2025, reflecting 5.7% operational growth, as per the earnings call.
Evaluation summary
Add to research
-
Company Overview:
- AbbVie, Inc. is a research-based biopharmaceutical company that develops and sells pharmaceutical products. Its key areas of focus include immunology, oncology, aesthetics, neuroscience, and eye care. Major products include Humira, Skyrizi, Rinvoq, Imbruvica, Venclexta, Elahere, Botox, and Juvederm. The company sells its products worldwide to wholesalers, distributors, healthcare facilities, and other customers.
- The company's product portfolio spans several therapeutic areas, with a significant portion of revenue derived from immunology and oncology products. While specific revenue breakdowns for each product are not provided in the given data, the SEC filings and earnings call transcripts highlight Skyrizi and Rinvoq as key growth drivers.
- The benchmarks used for comparative analysis are the Health Care Select Sector SPDR Fund (XLV), Regeneron Pharmaceuticals, Inc. (REGN), and Amgen, Inc. (AMGN).
-
Financial Performance:
- AbbVie's revenue has shown an upward trend throughout 2024, increasing from $12.31 billion in Q1 to $15.102 billion in Q4. However, the rate of revenue growth appears to be decelerating.
- The net profit margin has decreased significantly over the year, from 11.04% in Q1 to -0.21% in Q4. This decline is primarily due to increasing selling, general, and administrative expenses, which rose from $5.239 billion in Q1 to $10.534 billion in Q4, and unusual expenses, which increased from $845 million to $1.928 billion over the same period.
- AbbVie's Return on Average Assets (ROA) has decreased from 4.20% in Q1 to 3.14% in Q4. Similarly, the Return on Average Total Equity (ROE) has decreased from 55.92% to 61.94%, and the Return on Average Total Capital has decreased from 22.02% to 17.14%.
- Compared to the industry average, AbbVie's ROA, ROE, and ROIC are significantly higher, indicating better profitability relative to its assets, equity, and invested capital. However, the industry averages are negative, making direct comparison challenging.
- The earnings call highlighted that full-year adjusted EPS was $10.12, exceeding initial guidance. Total net revenues were $56.3 billion, also exceeding initial guidance.
-
Operational Efficiency:
- AbbVie's total current assets decreased from $38.871 billion in Q1 2024 to $25.582 billion in Q4 2024, while total current liabilities decreased from $41.522 billion to $38.749 billion over the same period.
- The company's working capital is negative, with a value of -$13.167 billion in Q4 2024. This indicates potential inefficiencies in managing short-term assets and liabilities.
- Net operating cash flow has fluctuated throughout the year, with a low of $2.271 billion in Q2 and a high of $7.048 billion in Q4. Net investing cash flow was consistently negative, reflecting investments in acquisitions and other assets. Net financing cash flow was also generally negative, primarily due to cash dividends paid and debt repayments.
- Free cash flow to equity has been positive, ranging from $2.030 billion in Q2 to $6.757 billion in Q4. The free cash flow margin has increased from 0.31 in Q1 to 0.45 in Q4, indicating improved cash generation relative to revenue.
- Capital expenditures have increased slightly throughout the year, from $193 million in Q1 to $291 million in Q4. Depreciation, depletion, and amortization expenses have remained relatively stable, around $2.1 billion per quarter.
- AbbVie has consistently paid dividends, with dividends per share at $1.64 in Q4 2024. The company has also engaged in share repurchases, as indicated by the change in capital stock.
- The current ratio has remained below 1 throughout the year, indicating potential liquidity challenges. The debt-to-equity ratio is very high, at 2040.33 in Q4 2024, indicating significant financial leverage.
-
Growth Opportunities:
- AbbVie is focused on expanding its market presence through strategic acquisitions, such as the completed acquisitions of ImmunoGen and Cerevel Therapeutics.
- The company is investing heavily in its R&D pipeline, with adjusted R&D expense at 15.1% of sales in Q4. This investment is aimed at developing new products and indications across its key therapeutic areas.
- While specific geographic expansion plans are not detailed in the provided data, the earnings call mentions that aesthetics sales have been impacted by challenging market conditions in the U.S. and China, suggesting a focus on stabilizing and growing these markets.
- AbbVie's current strategic focus areas include immunology, oncology, neuroscience, and aesthetics. The company is prioritizing the development and commercialization of innovative medicines and therapies in these areas.
- The earnings call highlighted that Skyrizi and Rinvoq are expected to generate nearly $24 billion in 2025, with combined sales exceeding $31 billion in 2027.
- AbbVie has significant capacity to continue pursuing external innovation with a focus on differentiated opportunities that can drive growth in the next decade.
-
Recent Developments and Market Sentiment:
- The SEC filings highlight AbbVie's strategic acquisitions of ImmunoGen and Cerevel Therapeutics, aimed at expanding its oncology and neuroscience pipelines. The appointment of Robert A. Michael as CEO and the strong financial performance in 2024, with 4% revenue growth and $2.39 EPS, reflect positive developments.
- The earnings call reveals that Skyrizi and Rinvoq are key growth drivers, while the aesthetics business faces near-term challenges. The Medicare Part D redesign is a significant headwind, impacting revenue by approximately 4%.
- Analysts are focused on pricing dynamics, growth drivers for key products, and the impact of Humira biosimilars. The partial impairment of the Cerevel intangible asset also raises concerns.
- Overall market sentiment appears mixed, with optimism surrounding the growth potential of Skyrizi and Rinvoq, but concerns about the aesthetics market and the impact of regulatory changes.
-
Risks and Threats:
- Key risks identified in the SEC filings include the loss of patent protection and increased competition from generics and biosimilars, particularly for Humira.
- Pricing and reimbursement pressures, including the impact of government policies like the Inflation Reduction Act, pose a significant threat to AbbVie's profitability.
- Reliance on third-party suppliers and manufacturers, potential product safety and efficacy issues, intellectual property challenges, and cybersecurity risks also represent significant threats.
- The ongoing antitrust litigation related to Niaspan and AndroGel patent settlements, as well as opioid-related lawsuits against Allergan, pose legal and financial risks.
-
Valuation Analysis:
- The Enterprise Value to EBITDA ratio has fluctuated throughout the year, ranging from 13.89 to 18.35. The Enterprise Value to Sales ratio has also varied, from 6.57 to 7.45.
- Compared to the industry average, AbbVie's EV/EBITDA and EV/Sales ratios are significantly lower, suggesting that the company may be undervalued relative to its earnings and sales.
- Potential catalysts for AbbVie include successful pipeline development, regulatory approvals for new products and indications, and effective management of Humira biosimilar competition.
-
Price Performance:
- AbbVie's stock price has shown volatility in recent months. From February 19, 2025, to April 17, 2025, the stock price decreased from $195.54 to $172.99.
- Compared to the Health Care Select Sector SPDR Fund (XLV), AbbVie has underperformed year-to-date, with returns of -1.79% compared to XLV's -1.16%. The one-month performance shows a significant underperformance by ABBV, with a -17.63% return compared to XLV's -7.48%.
- Compared to its peers, AbbVie has outperformed Regeneron Pharmaceuticals, Inc. (REGN) and Amgen, Inc. (AMGN) over the past three years, but recent performance has been weaker, particularly against Amgen.
-
Future Outlook:
- Management guidance for 2025 includes adjusted EPS between $12.12 and $12.32 and total net revenues of approximately $59 billion, reflecting 5.7% operational growth.
- The company expects a high single-digit revenue CAGR in aesthetics through 2029 and free cash flow approaching $17 billion in 2025.
- Recent news and developments, such as the Medicare Part D redesign and the ongoing Humira biosimilar competition, are expected to influence the company's future performance.
-
Summary:
- AbbVie is a research-based biopharmaceutical company with a diversified product portfolio and a strong focus on innovation. While the company has shown revenue growth, profitability has been declining due to increasing expenses. The company's liquidity position is weak, and it carries a high debt load.
- Strengths: Diversified product portfolio, strong R&D pipeline, strategic acquisitions, and high free cash flow.
- Weaknesses: Declining profitability, weak liquidity, high debt levels, and negative working capital.
- Opportunities: Market expansion through new products and indications, strategic partnerships, and geographic growth.
- Threats: Patent expirations, pricing pressures, competition from generics and biosimilars, regulatory risks, and legal challenges.
- Overall, AbbVie's financial health is mixed, with strengths in revenue generation and innovation offset by weaknesses in profitability and liquidity. The company's future performance depends on its ability to manage debt, control expenses, and sustain revenue growth through strategic initiatives and pipeline development. Investors should monitor the impact of Humira biosimilar competition, the integration of recent acquisitions, and the company's exposure to legal proceedings.
Price history
Add to research
Fundamentals
Add to research
Insights
- AbbVie's revenue is growing, but profitability is declining due to increasing operating expenses.
- The company's liquidity position is weak, with a current ratio below 1, indicating potential difficulties in meeting short-term obligations.
- AbbVie's debt-to-equity ratio is very high, indicating significant financial leverage and potential solvency risks.
- Effective debt management and expense control are crucial for AbbVie to improve its financial health and sustain long-term growth.
- Strategic initiatives, such as acquisitions and pipeline expansion, will play a crucial role in driving future earnings.
Analysis
-
Revenue - Revenue is on an upward trajectory, indicating successful sales strategies and market penetration. - However, the rate of revenue growth is decelerating, which could signal increasing competition or market saturation. - AbbVie's revenue is significantly higher than the industry average, reflecting its strong market position.
-
Profitability
- Profitability metrics, such as net profit margin and EBITDA margin, are decreasing, raising concerns about cost management.
- Despite the decline, AbbVie's profitability metrics are still higher than the industry average, showcasing its ability to generate profit.
- The company's gross profit margin is increasing, suggesting improved efficiency in production.
-
Liquidity
- Liquidity ratios, such as the current ratio and quick ratio, are below 1 and decreasing, indicating potential difficulties in meeting short-term obligations.
- AbbVie's liquidity position is weaker than the industry average, requiring careful monitoring and management.
- The company needs to improve its short-term financial health to ensure operational stability.
-
Solvency
- AbbVie's debt-to-equity ratio is very high and increasing, indicating significant financial leverage and potential solvency risks.
- While the debt/EBITDA ratio is lower than the industry average, the high debt-to-equity ratio warrants attention.
- Effective debt management is crucial for AbbVie to maintain long-term financial stability.
-
Operational Efficiency
- Selling, general, and administrative expenses are increasing significantly, impacting overall profitability.
- The company needs to focus on expense control to improve its bottom line and operational efficiency.
- Decreasing accounts receivable suggests efficient revenue collection.
-
Cash Flow Analysis - Net operating cash flow is generally positive, indicating AbbVie's ability to generate cash from its core operations. - However, changes in working capital are highly variable, influenced by factors like inventory management and accounts receivable collection. - Increasing capital expenditures reflect investments in property, plant, and equipment, supporting future growth.
-
Risk Factors
- High debt levels and decreasing equity pose significant financial risks.
- Declining profitability metrics and increasing operating expenses raise concerns about cost management.
- The loss of patent protection and increased competition from generics and biosimilars, as highlighted in the SEC filings, could further impact revenue and profitability.
-
Future Outlook
- AbbVie's future outlook depends on its ability to manage debt, control expenses, and sustain revenue growth.
- Strategic initiatives, such as acquisitions and pipeline expansion, will play a crucial role in driving future earnings.
- Management's focus on debt repayment and R&D investment is essential for long-term success.
-
Financial statements
Add to research
Loading...
Public filings
Add to research
- AbbVie has built a diversified portfolio of innovative pharmaceutical products across immunology, oncology, aesthetics, neuroscience, and eye care, with several key growth drivers like Skyrizi, Rinvoq, and Elahere
- The company has been actively expanding its pipeline and capabilities through strategic acquisitions like ImmunoGen and Cerevel Therapeutics, positioning it for future growth
- However, AbbVie faces significant risks from patent expirations, pricing/reimbursement pressures, product safety and efficacy issues, and legal/regulatory challenges that could impact its financial performance
- Management has demonstrated strong execution in navigating these challenges, maintaining profitability and cash flow, and investing in R&D to sustain the company's long-term growth
- Key risks to monitor include the ongoing impact of Humira biosimilars, the ability to successfully integrate and commercialize acquired assets, and the company's exposure to various legal proceedings
Core Business and Operations:
- AbbVie is a global, diversified research-based biopharmaceutical company focused on developing and commercializing innovative medicines and therapies
- Key product portfolio includes immunology, oncology, aesthetics, neuroscience, and eye care products, with major products including Humira, Skyrizi, Rinvoq, Imbruvica, Venclexta, Elahere, Botox, and Juvederm
- Products are sold worldwide directly to wholesalers, distributors, healthcare facilities, and other customers, with a significant portion of U.S. sales going through three major wholesalers
- Competes with other pharmaceutical and biotechnology companies in developing and marketing innovative products
Industry and Market Trends:
- Biopharmaceutical industry is highly competitive, with significant competition from generic and biosimilar products as patents expire
- Regulatory environment is complex, with extensive requirements for product development, manufacturing, and marketing approval
- Pricing and reimbursement pressures from governments, payers, and other stakeholders, including the impact of the Inflation Reduction Act in the U.S.
- Increasing importance of biologics and need for specialized manufacturing capabilities
Recent Events:
- Completed acquisitions of ImmunoGen (February 2024) and Cerevel Therapeutics (August 2024) to expand oncology and neuroscience pipelines
- Appointed Robert A. Michael as CEO, succeeding Richard A. Gonzalez who became Executive Chairman (July 2024)
- Received regulatory approvals for several new products and indications across immunology, oncology, and neuroscience
Risk Factors:
- Loss of patent protection and increased competition from generics and biosimilars
- Failure to successfully develop and commercialize new products
- Pricing and reimbursement pressures, including impact of government policies
- Reliance on third-party suppliers and manufacturers
- Potential product safety and efficacy issues
- Intellectual property challenges and litigation
- Cybersecurity and data privacy risks
Legal Matters:
- Ongoing antitrust litigation related to Niaspan and AndroGel patent settlements
- Opioid-related lawsuits against Allergan (acquired by AbbVie)
- Securities and product liability litigation
Management's Discussion and Analysis:
- Delivered strong financial performance in 2024, with 4% revenue growth and $2.39 EPS
- Significant revenue contributions from key growth drivers like Skyrizi, Rinvoq, and Elahere
- Continued investment in R&D pipeline and integration of recent acquisitions
- Managed impact of Humira biosimilar competition through diversified portfolio
- Maintained strong liquidity and access to capital, with $18.8 billion in operating cash flow
Earnings calls
Add to research
Earnings Report 2024Q4 (2025-01-31)
Key takeaways
- Skyrizi and Rinvoq are key growth drivers: Their strong performance and increased sales guidance indicate their importance in AbbVie's future.
- Aesthetics faces near-term challenges: Macroeconomic pressures and loyalty program adjustments are impacting sales, but long-term growth potential remains.
- Medicare Part D redesign is a significant headwind: The 4% negative impact on revenue highlights the importance of managing this change.
- Pipeline progress is crucial: Advancing key programs and pursuing external innovation are essential for long-term growth.
- M&A remains a strategic priority: AbbVie will continue to seek acquisitions to bolster its pipeline and drive growth in the next decade.
- Combination therapies in immunology are a key focus: AbbVie is actively pursuing co-formulation and bi-specific strategies to enhance treatment options.
- The eye care business is a strategic fit: Despite its smaller size, AbbVie sees long-term growth potential in this market, particularly with the REGENXBIO program.
Focus of management’s prepared remarks
- Overall Performance: AbbVie delivered an excellent year in 2024, executing on commercial priorities, advancing the pipeline, and strengthening the business through strategic transactions.
- Financial Results: Full-year adjusted EPS was $10.12, exceeding initial guidance. Total net revenues were $56.3 billion, also exceeding initial guidance.
- Ex-Humira Platform: The ex-Humira platform continues to outperform expectations, with full-year sales growth of more than 18% and revenue growth accelerating to 22% in Q4.
- Future Growth: AbbVie is well-positioned to deliver robust mid-single-digit revenue growth in 2025 and exceed previous peak revenue in the second year following the U.S. Humira LOE. A high single-digit revenue CAGR is expected through 2029.
- Skyrizi and Rinvoq: These assets are expected to collectively generate nearly $24 billion of revenue in 2025, reflecting growth of more than $6 billion. Combined sales are now expected to exceed $31 billion in 2027.
- Neuroscience: Neuroscience is performing robustly, with sales of $10 billion expected in 2025, reflecting growth across psychiatry, migraine, and Parkinson's.
- Oncology: Management is encouraged by long-term growth prospects in oncology, including Venclexta, Elahere, Teliso-V, ABBV-400, and ABBV-383.
- Aesthetics: While recent performance has been impacted by challenging market conditions, the category remains attractive given low penetration rates. A high single-digit revenue CAGR is expected through 2029.
- R&D Progress: Significant progress has been made with late-stage programs, including recent approvals for Skyrizi in UC, Epkinly, Elahere, Vyalev, and new indications for Botox and Juvéderm.
- Pipeline Expansion: Over 20 early-stage deals have been signed since the beginning of 2024, adding depth to the pipeline in immunology, oncology, and neuroscience.
- External Innovation: AbbVie has significant capacity to continue pursuing external innovation with a focus on differentiated opportunities that can drive growth in the next decade.
Focus of the analyst Q&A
- Skyrizi and Rinvoq Pricing Dynamics:
- Questions about pricing strategies and expectations for future pricing, including the impact of rebates and the Medicare Part D redesign.
- Skyrizi and Rinvoq Growth Drivers:
- Inquiries about the key factors driving the increased 2027 sales guidance, particularly the contribution from different indications like IBD.
- Questions about the expected growth rate of these franchises beyond 2027 and how mature they will be by then.
- Cerevel Revaluation:
- Questions regarding the drivers behind the partial impairment of the Cerevel intangible asset.
- Focus on the remaining value attributed to Tavapadon and Emraclidine.
- Aesthetics Market Recovery:
- Questions about whether 2025 is expected to be the trough year for aesthetics sales.
- Inquiries about the potential for BoNT/E to attract new patients to the aesthetics market.
- Medicare Part D Redesign Impact:
- Questions about the volume impacts assumed in the calculation of the net impact of the Part D redesign.
- ABBV-400 (Temab-A) Commercial Vision:
- Inquiries about the long-term commercial potential of ABBV-400 and its potential adoption in the early 2030s.
- M&A Strategy:
- Questions about AbbVie's agenda for future M&A activities, including leveraging existing franchise strengths.
- Impact of Humira Biosimilars:
- Questions about the impact of Humira biosimilars on Skyrizi and Rinvoq sales.
- Atopic Dermatitis Market Dynamics:
- Questions about the growth dynamics in the atopic dermatitis market and the potential for an inflection in Rinvoq sales.
- Inquiries about the role of lutikizumab in this indication.
- Aesthetics Market Share:
- Questions about the current market share for Botox and Juvéderm and the expected recovery following changes to the Alle loyalty program.
- Impact of Obesity Drugs on Aesthetics:
- Questions about the potential impact of obesity drugs on the aesthetics business, both as a headwind and a tailwind.
- PBM Reform:
- Questions about AbbVie's perspective on potential PBM reforms and desired changes to the relationship between PBMs and drug companies.
- Stocking and Gross-to-Net Patterns:
- Questions about any notable differences in stocking or gross-to-net patterns in Q4 ahead of changes in Part D.
- Geographic Split in Aesthetics Growth:
- Questions about the expected geographic split in aesthetics growth between the U.S., China, and other regions.
- Combination Approaches in Immunology:
- Questions about the potential impact of combination approaches in immunology beyond 2030, including IP implications and co-formulation strategies.
- Eye Care Business:
- Questions about the strategic fit of the eye care business within AbbVie's overall portfolio.
Summary
-
Financial Performance
AbbVie reported a strong fourth quarter and full-year 2024, exceeding initial guidance. Full-year adjusted EPS was $10.12, $0.49 above the initial guidance midpoint. Total net revenues were $56.3 billion, exceeding initial guidance by over $2 billion. Q4 adjusted EPS was $2.16, $0.08 above guidance midpoint, including an $0.88 unfavorable impact from acquired IPR&D expense. The company anticipates robust mid-single-digit revenue growth in 2025 and expects to exceed its previous peak revenue in the second year following U.S. Humira LOE.
-
Revenue Drivers
The primary revenue driver is the ex-Humira platform, which grew over 18% in 2024, accelerating to 22% in Q4. Skyrizi and Rinvoq are expected to generate nearly $24 billion in 2025, with combined sales exceeding $31 billion in 2027, $4 billion above previous guidance. Neuroscience is also a significant contributor, expected to reach $10 billion in 2025. Humira sales declined 48.7% operationally due to biosimilar competition. Aesthetics sales decreased 4.4% operationally due to challenging market conditions in the U.S. and China.
-
Profit Margins and Cost Management
Adjusted gross margin was 83.8% of sales in Q4. Adjusted R&D expense was 15.1% of sales, and adjusted SG&A expense was 23.6% of sales. The adjusted operating margin ratio was 34.7% of sales, including a 10.4% unfavorable impact from acquired IPR&D expense. For 2025, AbbVie forecasts a full-year adjusted gross margin of approximately 84% of sales, adjusted R&D investment of approximately 14.5%, adjusted SG&A expense of approximately $13.2 billion, and an adjusted operating margin ratio of roughly 47% of sales.
-
Guidance and Outlook
Full-year 2025 adjusted EPS guidance is between $12.12 and $12.32, excluding acquired IPR&D expense. Total net revenues are expected to be approximately $59 billion, reflecting 5.7% operational growth, despite a roughly 4% net unfavorable impact from the Medicare Part D benefit redesign. The company expects a high single-digit revenue CAGR in aesthetics through 2029. Free cash flow is expected to approach $17 billion in 2025.
-
Strategic Initiatives
AbbVie is focused on advancing its pipeline, with multiple regulatory submissions and clinical trial starts planned for 2025. The company has been actively pursuing external innovation, signing over 20 early-stage deals since the beginning of 2024. Debt repayment remains a priority, with nearly $3 billion of total debt expected to be paid down in 2025, remaining on track to achieve a net leverage ratio of 2x by the end of 2026.
-
Management Commentary
Management expressed confidence in AbbVie's execution and future growth prospects, highlighting the strength of the ex-Humira platform and the potential of the pipeline. The CEO emphasized the company's ability to deliver robust growth despite Humira erosion and other headwinds. Management also noted the long-term growth potential in aesthetics, despite near-term challenges.
-
Industry and Market Conditions
The company acknowledges challenging market conditions in the U.S. and China impacting aesthetics. They anticipate a gradual recovery in the aesthetics market. The immunology market is expected to continue growing, with high single-digit growth projected for psoriasis and IBD, and mid-teens growth for atopic dermatitis. The company also noted the impact of the Medicare Part D benefit redesign on revenue.
Comparative analysis
Add to research
Benchmarks (as of 2025-04-17)
Health Care Select Sector SPDR Fund (XLV)
-
Performance Comparison:
- AbbVie, Inc. (ABBV) has shown mixed performance compared to the Health Care Select Sector SPDR Fund (XLV). Over the past three years, ABBV has significantly outperformed XLV, with a 23.67% return compared to XLV's 1.38%. However, more recently, ABBV has underperformed XLV year-to-date, with returns of -1.79% and -1.16%, respectively. The one-month performance shows a significant underperformance by ABBV, with a -17.63% return compared to XLV's -7.48%.
-
Risk and Return Analysis:
- The annualized returns show that ABBV has provided higher returns than XLV over the 1, 2, and 3-year periods. For example, the 3-year annualized return for ABBV is 7.34%, while for XLV it is 0.46%.
- In terms of annualized volatility, ABBV generally exhibits higher volatility compared to XLV. For instance, in Q2 2024, ABBV's volatility ranged from 19.5% to 46.32%, while XLV's ranged from 8.21% to 15.72%. This indicates that ABBV's price movements are more pronounced than those of the broader health care sector represented by XLV.
- AbbVie, Inc. (ABBV) experienced a maximum drawdown of -21.92% on 2022-09-30, while the Health Care Select Sector SPDR Fund (XLV) had a maximum drawdown of -16.06% on 2022-06-17. This indicates that ABBV experienced a larger peak-to-trough decline than XLV, suggesting a higher risk profile.
-
Risk-Adjusted Performance:
- AbbVie, Inc. (ABBV) generally exhibited higher Sharpe Ratios compared to the Health Care Select Sector SPDR Fund (XLV) for much of the period analyzed, indicating better risk-adjusted returns. However, there were periods where XLV's Sharpe Ratio was higher, suggesting superior risk-adjusted performance during those specific times.
- The beta values for both AbbVie, Inc. (ABBV) and the Health Care Select Sector SPDR Fund (XLV) have remained consistently below 1 throughout the analyzed period, indicating that both ABBV and XLV are less volatile than the overall market. ABBV's lower beta suggests it is less sensitive to market movements compared to XLV.
-
Overall Assessment:
- AbbVie, Inc. (ABBV) has demonstrated strong historical performance over the past few years, outperforming the Health Care Select Sector SPDR Fund (XLV). However, recent performance indicates a significant underperformance in the last month and year-to-date. ABBV exhibits higher volatility and a larger maximum drawdown compared to XLV, suggesting a higher risk profile. Despite this, ABBV has generally provided better risk-adjusted returns, as indicated by its higher Sharpe Ratio. The lower beta of ABBV suggests it is less sensitive to overall market movements compared to XLV.
- Investors should be aware of ABBV's higher volatility and drawdown risk, particularly in the short term.
Peers Price History(as of 2025-04-17)
-
Performance Comparison:
- AbbVie Inc. (ABBV) has shown mixed performance compared to its peers. Over the past three years, ABBV has outperformed both Regeneron Pharmaceuticals, Inc. (REGN) and Amgen, Inc. (AMGN), with total returns of 23.67% compared to -21.64% for REGN and 19.33% for AMGN. However, more recently, ABBV has struggled, underperforming AMGN year-to-date (-1.79% vs 7.81%). The most significant outperformance was against REGN over 6 months (ABBV -5.52% vs REGN -41.78%) and 1 year (ABBV 6.78% vs REGN -37.36%).
-
Risk and Return Analysis:
- AbbVie Inc. (ABBV) has provided moderate annualized returns. Over the past three years, ABBV's annualized return was 7.34%, slightly higher than AMGN's 6.07% but significantly better than REGN's -7.81%. The annualized volatility for ABBV has been moderate, ranging from approximately 12.34 to 46.32. The maximum drawdown for ABBV was -20.67% on 2022-06-14, which is less severe than REGN's -54.48% on 2025-04-10 but comparable to AMGN's -24.86% on 2023-06-01. This indicates a moderate risk profile for ABBV.
-
Risk-Adjusted Performance:
- AbbVie Inc. (ABBV) has demonstrated a mixed risk-adjusted performance. The Sharpe Ratio for ABBV has fluctuated, with recent values indicating a decline. The beta value for ABBV has consistently been below 1, suggesting that the stock is less sensitive to market movements compared to its peers.
-
Overall Assessment:
- AbbVie Inc. (ABBV) presents a mixed investment profile when compared to Regeneron Pharmaceuticals, Inc. (REGN) and Amgen, Inc. (AMGN). While ABBV has shown strong historical performance over the past three years, recent performance has been weaker. The stock offers moderate returns with moderate volatility and a beta below 1, indicating lower market sensitivity. The Sharpe Ratio suggests fluctuating risk-adjusted returns, with recent declines. Investors should consider ABBV's historical outperformance and lower volatility, but also be aware of its recent underperformance and declining Sharpe Ratio.
Peers Fundamentals(as of 2024-12-31)
-
Market Position and Size:
- AbbVie stands out with a significantly larger market capitalization of $378,297 million compared to Regeneron ($77,348.6 million) and Amgen ($174,516 million).
- Its revenue ($56,334 million) and EBITDA ($20,493 million) also surpass those of its peers, indicating a strong market presence.
- Despite its size, AbbVie's net income ($4,238 million) is comparable to Regeneron ($4,412.6 million) and Amgen ($4,090 million), suggesting potential areas for improvement in profitability.
-
Profitability and Efficiency:
- AbbVie's gross profit margin (70.12%) is competitive, falling between Regeneron (82.73%) and Amgen (66.05%).
- Its EBITDA margin (36.38%) is also within the range of its peers, but its net profit margin (7.52%) lags behind Regeneron (31.07%) and Amgen (12.31%), indicating potential inefficiencies in cost management or higher expenses.
- Return on Average Total Capital is 17.14%, which is greater than Regeneron's 13.5% and Amgen's 12.61%.
-
Financial Health and Stability:
- AbbVie's current ratio (0.66) and quick ratio (0.55) are notably lower than its peers and industry averages, raising concerns about its short-term liquidity.
- Its total debt to total equity ratio is extremely high at 2040.33, significantly exceeding Regeneron (10.01) and Amgen (1035.89), indicating a high degree of financial leverage and potential solvency risks.
-
Valuation and Market Perception:
- AbbVie's Enterprise Value to Sales (6.69) and Enterprise Value to EBITDA (18.35) are higher than its peers, suggesting a premium valuation.
- Its Price to Earnings ratio (89.65) and Price to Book ratio (113.77) are also elevated compared to Regeneron and Amgen, indicating that the market has high expectations for its future earnings potential.
-
Cash Flow and Capital Management:
- AbbVie demonstrates strong cash flow generation, with a net operating cash flow of $18,806 million and free cash flow of $17,832 million, significantly exceeding its peers.
- However, its high debt levels raise questions about its capital allocation strategies and potential constraints on future investments.
-
Growth and Future Prospect:
- AbbVie's growth rates in sales/revenue, EBITDA, net income, and free cash flow have generally been lower than the peer group average over the past year.
- Its 3-year CAGR is lower than its 5-year CAGR for key metrics, indicating a deceleration in growth over the recent three-year period.
-
Potential for Investment:
- AbbVie's strong cash flow generation and dominant market position make it an attractive investment.
- However, its high debt levels, low liquidity, and decelerating growth rates pose significant risks that investors should carefully consider.
-
Key Risks and Considerations:
- High debt levels and potential solvency risks.
- Low liquidity and potential short-term financial constraints.
- Decelerating growth rates and potential loss of market share.
- Underperforming profitability margins compared to peers.
-
Overall Assessment:
- AbbVie is a large, well-established pharmaceutical company with a dominant market position and strong cash flow generation.
- However, its high debt levels, low liquidity, and decelerating growth rates raise concerns about its long-term financial health and competitive position.
- Investors should carefully weigh the potential benefits of its strong market presence against the risks associated with its financial leverage and growth deceleration.
Comparison metrics
Add to research